Precursor T-Cell Lymphoblastic Leukemia-Lymphoma: all 157 studies

Page 2 of 2. Open to participants first (66), then studies with results posted, then the rest; newest registration first within each.

• Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/LymphomaWithdrawnNCT05487495Phase 1
• Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic MalignanciesSuspendedNCT05377827Phase 1
• A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to TreatWithdrawnNCT05320380Phase 1/2
• Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell MalignanciesCompletedNCT05290155Phase 1
• NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALLTerminatedNCT05277753Phase 1
• Cryopreserved MMUD BM With PTCy for Hematologic MalignanciesWithdrawnNCT05170828Phase 1
• Venetoclax Based Regimen for R/R T-ALLCompletedNCT05149378Phase 2
• Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell MalignanciesStatus unknownNCT05127135Phase 1
• XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic LeukemiaTerminatedNCT05038644Phase 1
• Donor-Derived CD5 CAR T Cells in Subjects with Relapsed or Refractory T-Cell Acute Lymphoblastic LeukemiaTerminatedNCT05032599Phase 1
• A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBLCompletedNCT04984356Phase 1
• Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell MalignancesStatus unknownNCT04934774Phase 1
• A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBLWithdrawnNCT04860817Early Phase 1
• Phase I Clinical Trial of Autologous CD7-CAR T Cell Therapy for High-risk Acute T-cell Leukemia/lymphomaCompletedNCT04840875Phase 1
• Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell MalignanciesSuspendedNCT04828174Phase 1
• SPARK-ALL: Calaspargase Pegol in Adults With ALLTerminatedNCT04817761Phase 2/3
• Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological MalignanciesCompletedNCT04681105Phase 1
• the Efficacy and Safety of CLAE in R/R T-ALL/LBLStatus unknownNCT04679506
• Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell LymphomaWithdrawnNCT04639843Phase 1
• RD13-01 for Patients With r/r CD7+ T-ALL/T-LBLStatus unknownNCT04620655Not applicable
• Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell MalignanciesStatus unknownNCT04594135Phase 1
• Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T CellsCompletedNCT04572308Phase 1
• Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers PatientsStatus unknownNCT04446130Phase 3
• Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)Active, not recruitingNCT04315324Phase 1/2
• Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant SettingActive, not recruitingNCT04128501Phase 2
• Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic LeukemiaTerminatedNCT03808610Phase 1/2
• Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T CellsActive, not recruitingNCT03690011Phase 1
• Ruxolitinib Plus LVP in Patients With R/R ETP-ALLStatus unknownNCT03613428Phase 1/2
• EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute LeukemiaTerminatedNCT03519984Phase 1
• Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaActive, not recruitingNCT03007147Phase 3
• CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and LymphomaStatus unknownNCT02742727Phase 1/2
• Evaluation and Treatment of Tall Statured GirlsStatus unknownNCT02638922
• Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaWithdrawnNCT02538926Phase 2
• Romidepsin Maintenance After Allogeneic Stem Cell TransplantationCompletedNCT02512497Phase 1
• Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell TransplantationCompletedNCT02337595Phase 1/2
• Hyper-CVAD Treatment of Adult T-cell Acute Lymphoblastic Leukemia in Sweden.CompletedNCT01950286
• Studying Samples From Patients With T-Cell Acute Lymphoblastic LeukemiaCompletedNCT01581528
• Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell LymphomaCompletedNCT01567709Phase 1
• Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin LymphomaCompletedNCT01403415Phase 1
• Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic LymphomaCompletedNCT01363817Phase 1
• Biomarker Study in Bone Marrow Samples From Patients With T-Cell Acute Lymphoblastic LeukemiaCompletedNCT01295476
• Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell TransplantActive, not recruitingNCT01199562
• Veliparib and Temozolomide in Treating Patients With Acute LeukemiaCompletedNCT01139970Phase 1
• 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With CancerActive, not recruitingNCT00935090
• Studying Fentanyl in Patients With CancerTerminatedNCT00899951
• Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid MalignanciesTerminatedNCT00776373Phase 1/2
• Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma.TerminatedNCT00742495Phase 1/2
• 506U78 In Relapsed Or Refractory Acute Lymphoblastic Leukemia (T-ALL)CompletedNCT00684619Phase 2
• Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated LymphomaCompletedNCT00641381Phase 1
• Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid TumorsCompletedNCT00640796Phase 1
• Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By SurgeryCompletedNCT00608361Phase 1
• Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic LeukemiaCompletedNCT00437060
• Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment RegimensTerminatedNCT00419081Phase 2
• Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic CancerCompletedNCT00301951Phase 1
• Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)CompletedNCT00243087Phase 1
• A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)TerminatedNCT00100152Phase 1
• Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced CancerCompletedNCT00003451Phase 1

← Precursor T-Cell Lymphoblastic Leukemia-Lymphoma overview